Santen Pharmaceuticals Enters Into Worldwide License and Collaboration With Merck

Represented Japan-based global pharmaceutical company Santen Pharmaceuticals Co., Ltd. in its worldwide license and collaboration with Merck & Co., for tafluprost, a prostaglandin F2α analogue, for the treatment of glaucoma and ocular hypertension.